Acarbose for Longevity & Glucose Management — Aging
Alpha-glucosidase inhibitor FDA-approved for T2DM with positive NIA Interventions Testing Program lifespan data in mice.
Overview
Acarbose is an alpha-glucosidase inhibitor that reversibly blocks the enzymes responsible for breaking down complex carbohydrates into absorbable monosaccharides in the small intestinal brush border. FDA-approved for type 2 diabetes since 1995, acarbose has gained significant attention in the longevity field following positive results from the NIA Interventions Testing Program (ITP). In ITP studies, acarbose extended median lifespan by 22% in male mice and 5% in female mice when started at 4 months of age, and by 11% in males when started at 16 months (equivalent to late middle age). This sexual dimorphism is notable and may relate to differing metabolic responses. Acarbose's mechanism for longevity likely involves post-prandial glucose flattening, reduced insulin spikes, improved gut microbiome composition, and increased short-chain fatty acid production. Unlike metformin, acarbose works entirely within the GI tract with minimal systemic absorption (<2%), making it exceptionally safe systemically. The main limitation is GI tolerability — flatulence, bloating, and diarrhea are common due to undigested carbohydrates reaching the colon where bacterial fermentation produces gas.
Indications
- FDA-approved: Type 2 diabetes mellitus (adjunct to diet)
- Off-label: Postprandial hyperglycemia management
- Off-label: Longevity / anti-aging (based on ITP data)
- Off-label: Dumping syndrome after gastric surgery
Mechanism of Action
Reversibly inhibits alpha-glucosidase enzymes (maltase, isomaltase, sucrase, glucoamylase) in the small intestinal brush border
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Acarbose | 25 mg | Once daily with first bite of dinner | Starting dose for longevity; take with largest carbohydrate meal |
| Acarbose | 50 mg | With meals (1-3x daily) | Moderate dose; titrate slowly |
| Acarbose | 100 mg | Three times daily with meals | Maximum FDA-approved T2DM dose (>60 kg body weight) |
Evidence Grade
GRADE B
Safety & Contraindications
- Flatulence (77%), diarrhea (33%), abdominal pain (21%) — most common side effects
- GI symptoms improve with continued use over 4-8 weeks as gut microbiome adapts
- Elevated liver transaminases at doses >100 mg TID (rare, reversible)
- Hypoglycemia only when combined with insulin or sulfonylureas — treat with glucose (not sucrose, which acarbose blocks)
- Contraindicated in inflammatory bowel disease, intestinal obstruction, cirrhosis
- Minimal systemic absorption (<2%) — excellent systemic safety profile